Analysts Offer Predictions for ADCT Q3 Earnings

ADC Therapeutics SA (NYSE:ADCT) – HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of ADC Therapeutics in a research report issued to clients and investors on Wednesday, October 1st. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($0.38) per share for the quarter. The consensus estimate for ADC Therapeutics’ current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for ADC Therapeutics’ Q4 2025 earnings at ($0.39) EPS and FY2025 earnings at ($1.63) EPS.

ADC Therapeutics (NYSE:ADCT) last posted its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). The company had revenue of $18.84 million for the quarter, compared to analysts’ expectations of $17.82 million.

ADCT has been the topic of several other reports. Royal Bank Of Canada upgraded ADC Therapeutics from an “outperform” rating to a “moderate buy” rating and lowered their target price for the company from $8.00 to $5.00 in a research report on Friday, June 20th. Wall Street Zen downgraded shares of ADC Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. Guggenheim reissued a “buy” rating and set a $10.00 target price on shares of ADC Therapeutics in a research note on Wednesday, August 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ADC Therapeutics in a research report on Saturday, September 27th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.75.

ADC Therapeutics Stock Up 3.1%

ADC Therapeutics stock opened at $4.10 on Monday. The firm has a fifty day moving average of $3.23 and a 200-day moving average of $2.59. ADC Therapeutics has a 52-week low of $1.05 and a 52-week high of $4.31. The firm has a market capitalization of $461.70 million, a P/E ratio of -2.61 and a beta of 1.99.

Institutional Investors Weigh In On ADC Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Cerity Partners LLC acquired a new position in shares of ADC Therapeutics in the 1st quarter valued at $25,000. Atria Wealth Solutions Inc. acquired a new position in shares of ADC Therapeutics in the first quarter worth about $28,000. Russell Investments Group Ltd. boosted its holdings in shares of ADC Therapeutics by 136.3% in the first quarter. Russell Investments Group Ltd. now owns 39,688 shares of the company’s stock worth $56,000 after buying an additional 22,894 shares during the period. MetLife Investment Management LLC increased its position in shares of ADC Therapeutics by 46.2% in the first quarter. MetLife Investment Management LLC now owns 45,487 shares of the company’s stock worth $64,000 after acquiring an additional 14,370 shares in the last quarter. Finally, Creative Planning acquired a new stake in shares of ADC Therapeutics during the second quarter valued at approximately $96,000. 41.10% of the stock is owned by institutional investors and hedge funds.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.